39 / 64
PT2385: First‐In‐Class HIF‐2α Antagonist for the Treatment of RCC
Fase I; 52 pac CRCC
14% RR
52% EE
Courtney KD, Cell Renal Cell Carcinoma. J Clin Oncol. 2017 Dec 19;.2017.74.262–11.
|
|
39 / 64
39 / 64
PT2385: First‐In‐Class HIF‐2α Antagonist for the Treatment of RCC
Fase I; 52 pac CRCC
14% RR
52% EE
Courtney KD, Cell Renal Cell Carcinoma. J Clin Oncol. 2017 Dec 19;.2017.74.262–11.